Strategically focused on generating shareholder value by advancing our portfolio and identifying attractive investment opportunities with substantive upside potential Strategically focused on generati...
Company remains focused on generating shareholder value by advancing portfolio and identifying attractive opportunities for strategic investments...
Company remains focused on generating shareholder value by advancing our portfolio and identifying attractive opportunities for strategic investments Company remains focused on generating shareholder ...
Company positions itself to generate value for its stockholders by curtailing expenses while increasing investment in strategic opportunities Company positions itself to generate value for its stockho...
GAINESVILLE, Fla.--(BUSINESS WIRE)--Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changin...
Cranbury, NJ, June 01, 2022 (GLOBE NEWSWIRE) -- Cornerstone Pharmaceuticals, Inc. (“Cornerstone” or the “Company”), a company focused on rare cancer therapeutics and formerly known as Rafael P...
A clinical trial failure with the company's lead candidate has investors running for the exits....
New York, New York--(Newsfile Corp. - October 18, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Rafael Holdings, Inc. ("Rafael Hold...
NEWARK, N.J., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE: RFL), announced that today it made a grant to Dr. Mary Margaret Huizinga of options to purchase 122,341 shares of Class B...
We expect Rafael Pharmaceuticals to report top line data from its AVENGER 500 Phase 3 registrational clinical trial in metastatic pancreatic cancer this calendar year...
NEWARK, N.J., Oct. 6, 2021 /PRNewswire/ -- Rafael Holdings, Inc., (NYSE: RFL), a pharmaceutical holding company focused on developing novel cancer metabolism therapeutics through its Barer Institute ...